Barclays lowered the firm’s price target on Xencor (XNCR) to $6 from $22 and keeps an Underweight rating on the shares post the Q1 report. The firm continues to “de-risk” its biotech models.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR: